Vivesto AB 2022 AR2
The report highlights Vivesto's transition during 2022, including its name change from Oasmia Pharmaceutical AB to Vivesto AB and a strategic focus on oncology and veterinary oncology. The company advanced its clinical programs, including Cantrixil and Docetaxel micellar, and supported the commercial launch of Apealea in Germany. Financially, Vivesto raised approximately MSEK 151 through a rights issue, while also deciding to wind down its activities in Russia and write down assets related to Apealea due to commercialization uncertainties. Additionally, the company reduced its workforce to 18 employees and continued developing its next-generation drug delivery technology, XR-18.
Company: Vivesto AB
Sector: Health Care
Country: Sweden
Year: 2022
Type: AR2
Pages: 80
Vivesto AB
Annual Report
The report highlights Vivesto's transition during 2022, including its name change from Oasmia Pharmaceutical AB to Vivesto AB and a strategic focus on oncology and veterinary oncology. The company advanced its clinical programs, including Cantrixil and Docetaxel micellar, and supported the commercial launch of Apealea in Germany. Financially, Vivesto raised approximately MSEK 151 through a rights issue, while also deciding to wind down its activities in Russia and write down assets related to Apealea due to commercialization uncertainties. Additionally, the company reduced its workforce to 18 employees and continued developing its next-generation drug delivery technology, XR-18.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees